Welcome to our dedicated page for Integrated Biopharma SEC filings (Ticker: INBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integrated BioPharma, Inc. (INBP) files a range of documents with the U.S. Securities and Exchange Commission that provide insight into its business of manufacturing, distributing, marketing and selling vitamins, nutritional supplements and herbal products. These SEC filings include current reports on Form 8-K, annual reports on Form 10-K referenced in proxy materials, and definitive proxy statements on Schedule 14A.
For INBP, Form 8-K filings frequently report financial results for specific quarters and fiscal years under Item 2.02 (Results of Operations and Financial Condition). These filings typically furnish an earnings press release as an exhibit, summarizing revenue, operating income or loss, net income or loss and related per-share data, along with commentary on revenue concentration in the Contract Manufacturing Segment and performance of the nutraceutical business.
The company’s definitive proxy statement (DEF 14A) describes corporate governance and stockholder voting matters, including the election of a Class III director for a three-year term, advisory votes on executive compensation and the frequency of such votes, and ratification of the independent auditor for a specified fiscal year. It also explains record dates, voting procedures and quorum requirements for the annual meeting of stockholders.
Form 8-K filings related to the annual meeting disclose final voting results for director elections, advisory compensation proposals, advisory frequency of vote on executive compensation and auditor ratification. Together, these filings allow investors to review Integrated BioPharma’s financial reporting, governance structure and stockholder decisions.
On this page, SEC filings for INBP are updated from EDGAR as they become available. AI-powered tools can help summarize lengthy documents, highlight key items such as revenue trends, customer concentration in the Contract Manufacturing Segment, and outcomes of stockholder votes, and make it easier to interpret the implications of the company’s 10-K, 8-K and proxy disclosures.
INTEGRATED BIOPHARMA INC insider reporting reflects non-market gifts of Common Stock by entities associated with the late Carl DeSantis. CD Financial, LLC transferred 1,356,293 shares and the Carl DeSantis Revocable Trust transferred 7,392 shares to CDDS 2.0, LLC, a Florida LLC controlled by Damon DeSantis. After these bona fide gifts, a total of 11,366,673 shares of Common Stock remain indirectly held through CD Financial, LLC, the revocable trust and the Estate of Carl DeSantis.
Integrated BioPharma director and 10% owner William H. Milmoe reported two bona fide gifts of Common Stock made through entities he is associated with. On March 24, 2026, 1,356,293 shares were transferred from CD Financial, LLC to CDDS 2.0, LLC, and 7,392 shares were transferred from the Carl DeSantis Revocable Trust to the same LLC controlled by Damon DeSantis. These are non-cash, indirect transfers rather than market sales. After the gifts, Milmoe’s reported holdings across CD Financial, the revocable trust, the Estate of Carl DeSantis, and his direct ownership total 11,505,340 shares of Integrated BioPharma Common Stock.
INTEGRATED BIOPHARMA INC director Damon DeSantis reported bona fide gift transfers involving 1,363,685 shares of Common Stock. The transactions, coded as gifts, were recorded at a price of $0.00 per share and are held indirectly through CDDS 2.0, LLC.
Footnotes state that 1,356,293 shares were transferred from CD Financial, LLC and 7,392 shares from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC, which is controlled by DeSantis. Following these transfers, he indirectly holds 1,363,685 shares of the company’s common stock.
Integrated BioPharma Inc., through its wholly owned subsidiary Manhattan Drug Company, amended a long-term related-party lease for its office and warehouse space. The amendment reduces leased space from 116,175 to 110,095 square feet but raises annual basic rent from $845,966 to $1,100,950, with rent increasing three percent per year. The lease term is extended to a new termination date of January 31, 2029. Manhattan Drug Company will also continue to pay its proportionate share of the landlord’s operating expenses as additional rent. The landlord, Vitamin Realty Associates, is 100% owned by the estate of the company’s former chairman, a major stockholder, and the Co-Chief Executive Officers, who are also directors, making this a related-party arrangement.
Integrated BioPharma, Inc. reported weaker results for the quarter ended December 31, 2025, moving from profit to loss. Quarterly revenue fell to about $11.3 million from $12.6 million a year earlier, a 10.3% decline, and operating results shifted from roughly $0.2 million of income to a $0.9 million loss.
For the six-month period, revenue decreased to about $24.0 million from $26.2 million, and operating performance moved from approximately $0.7 million of income to a $0.7 million loss. The company recorded a net loss of $0.8 million for the quarter and $0.6 million for six months, versus net income of about $0.1 million and $0.4 million in the prior-year periods, with diluted earnings per share declining from $0.00 to $(0.03) for the quarter and from $0.01 to $(0.02) for six months.
Management noted that revenue from the two largest customers in the Contract Manufacturing Segment represented approximately 89% of total revenue for the six months ended December 31, 2025, up from 82% a year earlier, underscoring significant customer concentration.
Integrated BioPharma, Inc. reported weaker results for the quarter and six months ended December 31, 2025, as lower sales and thinner margins led to losses. Quarterly net sales fell to $11.3 million from $12.6 million, and the company swung to a net loss of $0.8 million versus prior-year profit.
For the six-month period, net sales declined to $24.0 million from $26.2 million, while net income of $0.4 million a year earlier turned into a net loss of about $0.6 million. Gross margin compressed significantly as cost of sales rose as a percentage of revenue, reflecting lower volumes to cover fixed manufacturing costs and pressure from inflation and labor markets.
The business remains highly concentrated, with two contract manufacturing customers accounting for roughly 89% of six‑month net sales. Despite the loss, liquidity improved: cash increased to $5.3 million, operating cash flow reached $1.9 million, and the company had no borrowings under its up to $4.5 million credit facilities, supporting working capital of about $14.3 million.
Integrated BioPharma Inc. reported an equity award to a senior insider. On 12/09/2025, Co-Chief Executive Officer, director and 10% owner Christina Kay received a stock option covering 140,000 shares of common stock at an exercise price of $0.35 per share. Following this grant, she beneficially owns 140,000 derivative securities in the form of this option. The option vests in three equal annual installments, with the first tranche vesting on December 9, 2026, aligning her compensation with longer-term shareholder performance.
Integrated BioPharma Inc. reported a new equity award to its Co-Chief Executive Officer and director, Riva Sheppard. On 12/09/2025, Sheppard received a stock option to purchase 140,000 shares of common stock at an exercise price of $0.35 per share. The option has an expiration date of December 9, 2035 and vests in three equal annual installments, with the first tranche vesting on December 9, 2026. Following this grant, Sheppard holds 140,000 derivative securities directly.
Integrated BioPharma Inc. reported a new stock option grant to its Chief Financial Officer, Dina L. Masi. On 12/09/2025, she received an option to purchase 140,000 shares of the company’s common stock at an exercise price of $0.31 per share. The option has an expiration date of 12/09/2035, giving a long-term window to exercise.
The option vests in three equal annual installments, with the first installment becoming exercisable on December 9, 2026. This means the grant is designed as a multi-year incentive, aligning the CFO’s potential equity gains with the company’s performance over time.
Integrated BioPharma, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 1, 2025. Of 31,059,610 common shares entitled to vote as of October 17, 2025, holders of 22,651,488 shares were present in person or by proxy, establishing a quorum.
Stockholders elected Class III director Eric Friedman to serve until the 2028 Annual Meeting, with 20,662,516 votes for, 183,398 withheld and 1,805,574 broker non-votes. They approved, on a non-binding basis, holding the advisory vote on executive compensation every three years, with 20,395,034 votes supporting a three-year frequency.
Stockholders also gave non-binding approval to the executive compensation for the named executive officers, with 20,788,236 votes for, 56,978 against and 700 abstentions, plus 1,805,574 broker non-votes. In addition, they ratified the appointment of CBIZ CPAs P.C. as independent auditors for the fiscal year ending June 30, 2026, with 22,536,930 votes for, 113,420 against and 1,138 abstentions.